Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Regulus Therapeutics Inc. (RGLS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3449+0.0049 (+1.44%)
At close: 04:00PM EST
0.3400 -0.00 (-1.42%)
After hours: 04:24PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.3400
Open0.3360
Bid0.3400 x 1100
Ask0.3550 x 1300
Day's Range0.3180 - 0.3519
52 Week Range0.3180 - 2.3200
Volume1,429,898
Avg. Volume2,076,363
Market Cap50.345M
Beta (5Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-0.3100
Earnings DateNov 10, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for RGLS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Regulus Therapeutics Inc.
    Analyst Report: Alnylam Pharmaceuticals, Inc.Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.
    Rating
    Fair Value
    Economic Moat
    2 days agoMorningstar
View more
Advertisement
Advertisement